Form 4: Erasca Director Opts for Stock Options Over Cash

Erasca Director Alexander W. Casdin received 23,872 stock options with a $3.72 exercise price in lieu of 2026 cash compensation.

Summary

• Alexander W. Casdin, a Director and 10% Owner of Erasca, Inc. (ERAS), acquired 23,872 stock options.
• The options have an exercise price of $3.72 per share.
• The transaction date for the option grant was January 1, 2026.
• These options were granted in lieu of cash compensation for Casdin's anticipated service on the board of directors and its committees in 2026.
• The options will vest in monthly, cumulative 1/12 increments beginning one month from the grant date, subject to Casdin's continued service on the board.
• The expiration date for these options is January 1, 2036.
• Following this transaction, Casdin directly beneficially owns 23,872 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The director's choice to receive equity compensation instead of cash suggests confidence in the company's future prospects and aligns his financial interests with long-term shareholder value.

Positives

• Director Alexander W. Casdin elected to receive stock options instead of cash compensation for his 2026 board service, indicating alignment of his interests with long-term shareholder value.
• The grant of 23,872 stock options ties a portion of the director's compensation directly to the company's future stock performance.

Risks

• The vesting of the 23,872 stock options is contingent upon Alexander W. Casdin's continued service on Erasca's board of directors through the applicable vesting dates.

Future Outlook

The director's compensation structure for 2026 includes equity-based incentives, aligning his future financial interests with the company's stock performance. The vesting schedule encourages continued board service.

Management Comments

• "At the election of the filing person the option grant was issued in lieu of the cash compensation payable to such person in 2026 in connection with each position on the issuer's board of directors and its committees for which such person is anticipated to serve in 2026."
• "The option will vest and become exercisable in monthly, cumulative 1/12 increments beginning one month from the date of grant, subject to such person continuing to serve on the issuer's board of directors through the applicable vesting date."

Industry Context

It is a common practice in the biotechnology and broader corporate sectors for directors to receive a portion of their compensation in equity, such as stock options, to align their interests with those of shareholders and incentivize long-term value creation. This practice is particularly prevalent in growth-oriented companies like Erasca, Inc.

Comparison to Industry Standards

• The practice of granting stock options to directors in lieu of cash compensation is a widely accepted corporate governance standard, particularly in industries where long-term strategic vision and alignment with shareholder interests are paramount.
• Many biotech companies, similar to Erasca, utilize equity compensation to attract and retain experienced board members.
• The structure of this compensation aligns with general industry benchmarks for director remuneration, which often include a mix of cash and equity.

Stakeholder Impact

• Shareholders: The decision by a director to take equity compensation aligns his interests with those of shareholders, potentially fostering a stronger commitment to long-term value creation.

Next Steps

• Alexander W. Casdin is anticipated to continue serving on Erasca's board of directors and its committees in 2026 to fulfill the vesting conditions of the stock options.

Key Dates

Keywords

Erasca, ERAS, stock options, director compensation, insider transaction, Form 4, equity compensation, corporate governance, Alexander W. Casdin, beneficial ownership